Diagnostic Markers of Neuropathic Odontalgia

• Conditions: Oral Mucosa

• Registration Number: NCT04142918
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

The DIAMOND study aims to investigate the presence and diagnostic relevance of potential biomarkers of the blood-nerve barrier disruption as surrogate markers of painful post-traumatic trigeminal neuropathic pain in patients presenting with neuropathic odontalgia. The first part of the study explores the proof-of-concept and technical feasibility of intra-epithelial nerve fiber immunostaining in gingival/oral mucosa biopsies and the potential presence of these biomarkers in healthy patients (baseline condition).

Detailed Description

Painful Post-Traumatic Trigeminal Neuropathy (PPTTN) defines a neuropathic painful condition affecting the orofacial region, following local nerve trauma, usually secondary to dental treatments (tooth avulsion, root canal treatments....). It often presents as odontalgia of atypical presentation, unresponsive to conventional treatments. The diagnostic is often complex (and often is a diagnosis of elimination), leading to unnecessary iatrogenic dental treatments and insufficient pain relief.

This study aims to explore potential new markers of PPTTN, based on a translational approach following previous preclinical work that showed the importance of the disruption of the blood-nerve barrier in generating post-traumatic neuropathic pain. Several markers of such disruption have been highlighted (such as Claudin-5, Patched-1 and Frizzled-7) that could be specifically downregulated in neuropathic pain conditions (as compared to inflammatory neuritis conditions). As such, these markers could be interesting biomarkers of neuropathic pain. This study aims to explore the presence (and absence) of such markers in healthy vs neuropathic patients respectively.

The first part of the study investigates the technical feasibility of intra-epithelial nerve fiber staining in oral mucosa/gingiva specimens collected in healthy patients (undergoing routine oral surgery procedures) and the immunoreactivity/presence of such biomarkers in those specimens.

Study Timeline

• Study First Submitted: 2019-10-25
• Study First Submitted QC: 2019-10-25
• Study First Posted: 2019-10-29
• Status Verified: 2020-03
• Last Update Submitted: 2020-03-24
• Last Update Posted: 2020-03-25
• Study Start: 2020-06-01
• Primary Completion: 2020-12-01
• Study Completion: 2021-03-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Adult patients (over 18 years old) requiring an oral/dental surgical intervention that will generate gingival/mucosal tissue elimination (as part of the normal surgical procedure)

Read More

Exclusion Criteria

• Patient with a diagnosed odontalgia
• Patient with Painful Post-Traumatic Trigeminal Neuropathy (PPTTN)
• Patient with unexplained pains or a neuropathic pain regardless of its location
• Patient under guardianship or trusteeship
• Patient who refuses to give his/her non-opposition to participate to the study

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patched-1 Western Blot concentration	Baseline	Patched-1 will be measured in oral mucosa/gingiva samples using Western Blot
Patched-1 immunohistochemistry concentration	Baseline	Patched-1 will be measured in oral mucosa/gingiva samples using immunohistochemistry (IHC)
Patched-1 ELISA concentration	Baseline	Patched-1 will be measured in oral mucosa/gingiva samples using ELISA
Frizzled-7 ELISA concentration	Baseline	Frizzled-7 will be measured in oral mucosa/gingiva samples using ELISA
Claudin-5 immunohistochemistry concentration	Baseline	Claudin-5 will be measured in oral mucosa/gingiva samples using immunohistochemistry (IHC)
Frizzled-7 Western Blot concentration	Baseline	Frizzled-7 will be measured in oral mucosa/gingiva samples using Western Blot
Frizzled-7 immunohistochemistry concentration	Baseline	Frizzled-7 will be measured in oral mucosa/gingiva samples using immunohistochemistry (IHC)
Claudin-5 Western Blot concentration	Baseline	Claudin-5 will be measured in oral mucosa/gingiva samples using Western Blot
Claudin-5 ELISA concentration	Baseline	Claudin-5 will be measured in oral mucosa/gingiva samples using ELISA

Trial Locations

Locations (1)

Bretonneau Hospital; 🇫🇷 Paris, France